Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease.
Wijeyekoon, Ruwani S
Breen, David P
Movement disorders : official journal of the Movement Disorder Society
MetadataПоказать полную информацию
Wijeyekoon, R. S., Moore, S. F., Farrell, K., Breen, D. P., Barker, R., & Williams-Gray, C. (2020). Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease.. Movement disorders : official journal of the Movement Disorder Society, 35 (6), 1062-1066. https://doi.org/10.1002/mds.28015
Introduction- Immune markers are altered in Parkinson’s disease (PD), but relationships between cerebrospinal fluid (CSF) and plasma cytokines, and associations with neurodegeneration-associated proteins remain unclear. Methods- CSF and plasma samples and demographic/clinical measures were obtained from 35 PD patients. CSF samples were analysed for cytokines (together with plasma), and for alpha-synuclein, amyloid beta(1-42) peptide, total tau and phospho(Thr231)-tau. Results- There were no CSF-plasma cytokine correlations. IL-8 was higher and IFN-γ, IL-10 and TNF-α were lower in CSF versus plasma. In CSF, total tau correlated positively with IL-8 and IL-1β, while alpha-synuclein correlated positively with amyloid beta(1-42) and negatively with semantic fluency (known marker of PD dementia risk). Discussion- CSF and peripheral cytokine profiles in PD are not closely related. Associations between CSF IL-8 and IL-1β, and tau suggest CSF inflammatory changes may relate to tau pathology within PD. CSF alpha-synuclein/amyloid beta may reflect the risk of developing PD dementia.
Humans, Parkinson Disease, Peptide Fragments, tau Proteins, Cytokines, alpha-Synuclein, Amyloid beta-Peptides, Biomarkers
Funding for this work was provided by the Rosetrees Trust (M369-F1), Addenbrooke’s Charitable Trust (PF15/CWG) and the NIHR Cambridge Biomedical Research Centre Dementia and Neurodegeneration Theme (146281). RSW was supported by a Fellowship from Addenbrooke’s Charitable Trust (RG77199). SFM was supported by the Transeuro EU FP7 grant (242003) and is now an NIHR Academic Clinical Fellow (ACF-2015-23-501). DPB is supported by a Wellcome Trust Clinical Research Career Development Fellowship. RAB is an NIHR Senior Investigator (NF-SI-0616-10011) and is supported by the Wellcome Trust-MRC Cambridge Stem Cell Institute. CHWG holds a RCUK/UKRI Research Innovation Fellowship awarded by the Medical Research Council (MR/R007446/1) and receives support from the Cambridge Centre for Parkinson-Plus.
Addenbrooke's Charitable Trust (ACT) (9968 MINUTE NO 24/14B)
Addenbrooke's Charitable Trust (ACT) (PF15/CWG)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Medical Research Council (MC_PC_17230)
Embargo Lift Date
External DOI: https://doi.org/10.1002/mds.28015
This record's URL: https://www.repository.cam.ac.uk/handle/1810/302418
All rights reserved